- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Peripheral Artery Disease Pipeline Advances with 20+ Companies Developing 22+ Therapies
New report analyzes clinical trial progress, mechanisms of action, and routes of administration for upcoming treatments.
Apr. 15, 2026 at 2:32pm
Got story updates? Submit your updates here. ›
A detailed X-ray view of the complex vascular network in the human leg, highlighting the challenges of treating peripheral artery disease.Las Vegas TodayAccording to a new assessment by DelveInsight, the global pipeline for Peripheral Artery Disease (PAD) includes over 20 key companies working on developing more than 22 different treatment therapies. The report provides an in-depth analysis of the current clinical trial progress, mechanisms of action, and routes of administration for these upcoming PAD therapies.
Why it matters
Peripheral Artery Disease is a serious circulatory condition that can lead to leg pain, mobility issues, and in severe cases, amputation. With an aging population and rising rates of diabetes, the need for new and improved PAD treatments is critical. This pipeline analysis sheds light on the innovative approaches companies are taking to address this unmet medical need.
The details
The DelveInsight report examines the current state of the PAD pipeline, including details on the various mechanisms of action and routes of administration being explored by pharmaceutical companies. Some of the key therapeutic approaches include novel anti-inflammatory agents, gene therapies, and devices designed to improve blood flow.
- The report was published on April 15, 2026.
The players
DelveInsight
A leading healthcare intelligence and consulting firm that provides market research and analysis on the pharmaceutical industry.
What’s next
The report provides a comprehensive overview of the PAD pipeline, giving healthcare providers and investors a detailed look at the latest advancements in this critical therapeutic area.
The takeaway
With a robust pipeline of 22+ novel PAD therapies in development, there is growing hope that new treatment options will soon be available to improve outcomes for the millions of people living with this debilitating circulatory condition.
